<DOC>
	<DOCNO>NCT00296517</DOCNO>
	<brief_summary>This study design evaluate efficacy safety depressive patient respond sufficiently selective serotonin re-uptake inhibitor ( SSRI ) .</brief_summary>
	<brief_title>Study In Patients With Depression Not Responding Selective Serotonin Re-uptake Inhibitors</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Serotonin</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<criteria>Inclusion criterion : [ At start pretreatment phase ] Target disease : Patients diagnose follow primary disease basis DSMIVTR criterion . Major Depressive Disorder , Single Episode ( 296.2x ) ( exclude psychotic feature ) Major Depressive Disorder , Recurrent ( 296.3x ) ( exclude psychotic feature ) HAMD ( 17 item ) total score &gt; =16 . Patients treat marketed paroxetine ( Paxil® ) 20mg/day 40mg/day 4 week start pretreatment phase . Age : &gt; =18 year old ( time inform consent ) , &lt; 65 year old ( start treatment phase ) Gender : Male female . Inpatients outpatient : Either Informed consent : The subject himself/herself must give write informed consent . However , subject 20 time give consent , subject himself/herself his/her legally acceptable representative must give write informed consent . [ At end pretreatment phase ] 1 . HAMD ( 17 item ) total score ≥14 . 2 . Percentage change start pretreatment phase HAMD ( 17 item ) total score &lt; 50 % [ At start treatment phase ] 1 . HAMD ( 17 item ) total score ≥14 . 2 . Percentage change start pretreatment phase HAMD ( 17 item ) total score &lt; 50 % [ At start pretreatment phase ] Patients complication glaucoma Patients concomitantly use drug increase risk bleeding patient bleed tendency predisposition bleed Patients predisposition seizure ( currently past history seizure , febrile convulsive seizure infancy , cerebral tumour , cerebrovascular disorder head injury , family history idiopathic seizure , patient diabetes treat oral hypoglycaemics insulin , use drug lower threshold seizure ) . Patients currently past history follow disorder : Anorexia nervosa ( DSMIVTR 307.1 ) Bulimia nervosa ( DSMIVTR 307.51 ) Patients history manic episode Patients past current DSM IVTR diagnosis schizophrenia psychotic disorder Patients current DSMIVTR Axis II diagnosis ( e.g. , antisocial borderline personality disorder ) Patients start psychotherapy ( except supportive psychotherapy aim therapeutic efficacy unlikely affect efficacy evaluation ) formal cognitive behaviour therapy within 5 week prior start pretreatment phase Patients diagnosis substance abuse ( alcohol drug ) DSMIVTR criterion diagnosis substance dependence within 1 year prior start pretreatment phase Patients receive electroconvulsive therapy within 17 week prior start pretreatment phase Patients take MAO inhibitor ( selegiline hydrochloride ) within 2 week prior start pretreatment phase Patients take another investigational drug within 12 week prior start pretreatment phase Female patient pregnant , possibly pregnant nursing , want become pregnant 30 day last dose investigational product Patients attempted suicide within 17 week prior start pretreatment phase , patient score suiciderelated item No . 3 HAMD &gt; =3 , patient risk suicide judge high investigator ( subinvestigator ) Patients risk homicide judge high investigator ( subinvestigator ) Patients history hypersensitivity 323U66 and/or paroxetine Patients serious cerebral disease Patients ECG clinical evidence cardiac condition investigator ( subinvestigator ) feel may predispose subject ischemia arrhythmia Patients serious physical symptom ( i.e . cardiac/hepatic/renal disorder , hematopoietic disorder ) The index seriousness Grade 3 `` Criteria classification seriousness adverse drug reaction pharmaceutical product , etc . '' ( PAB/PSD No.80 1992 ) . Patients history complication cancer malignant tumour . Patients whose major depressive disorder due direct physiological effect general medical condition ( example , hypothyroidism , Parkinson 's disease , chronic pain ) Patients systolic blood pressure &gt; =160 mmHg diastolic blood pressure &gt; =100 mmHg Patients inappropriate participate study judgement investigator ( subinvestigator ) [ At start treatment phase ] 1 . Patients whose compliance paroxetine pretreatment phase le 70 % . 2 . Patients ECG clinical evidence cardiac condition investigator ( subinvestigator ) feel may predispose subject ischemia arrhythmia 3 . Patients systolic blood pressure &gt; =160 mmHg diastolic blood pressure &gt; =100 mmHg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>bupropion hydrochloride</keyword>
	<keyword>SSRI</keyword>
	<keyword>non-responder</keyword>
	<keyword>depression</keyword>
	<keyword>placebo-controlled</keyword>
	<keyword>double-blind</keyword>
	<keyword>comparative study</keyword>
</DOC>